Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Plasma levels of activated factor VII decrease during the menstrual cycle

S Kapiotis1, B Jilma, T Pernerstorfer

  • 1Department of Clinical Pharmacology-TARGET, General Hospital Vienna, University of Vienna, Austria. stylianos.kapiotis@univie.ac.at

Thrombosis and Haemostasis
|November 3, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Camostat Mesylate Versus Lopinavir/Ritonavir in Hospitalized Patients With COVID-19-Results From a Randomized, Controlled, Open Label, Platform Trial (ACOVACT).

Frontiers in pharmacology·2022
Same author

Comparative proteomics reveals unexpected quantitative phosphorylation differences linked to platelet activation state.

Scientific reports·2019
Same author

PCSK9 decreases during experimental endotoxemia.

Journal of internal medicine·2019
Same author

Added value of the DIC score and of D-dimer to predict outcome after successfully resuscitated out-of-hospital cardiac arrest.

European journal of internal medicine·2018
Same author

Statistical analysis of Goal Attainment Scaling endpoints in randomised trials.

Statistical methods in medical research·2018
Same author

Anti-C1s monoclonal antibody BIVV009 in late antibody-mediated kidney allograft rejection-results from a first-in-patient phase 1 trial.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2017
Same journal

Anti-TFPI Single-Domain Antibodies: Novel Rebalancing Therapies for Hemophilia and Other Rare Bleeding Disorders.

Thrombosis and haemostasis·2026
Same journal

The Interaction of Fibrin with Endothelial Cell Receptor N-Cadherin Promotes Fibrin-Dependent Angiogenesis.

Thrombosis and haemostasis·2026
Same journal

Antiphospholipid Antibodies and Atrial Fibrillation: Clinical Implications and the TaPL AF Study Design.

Thrombosis and haemostasis·2026
Same journal

Prasugrel vs. Ticagrelor: Can TUXEDO-2 Settle the Debate?

Thrombosis and haemostasis·2026
Same journal

Methylglyoxal Promotes RBC-Driven Procoagulant Activity and Venous Thrombosis under Diabetes-Relevant Conditions.

Thrombosis and haemostasis·2026
Same journal

Management of Inferior Vena Cava Thrombosis: Guidance from the Italian Society for the Study of Haemostasis and Thrombosis.

Thrombosis and haemostasis·2026
See all related articles

Men exhibit higher activated factor VII (FVIIa) levels than women, with FVIIa fluctuating during the menstrual cycle. Female hormones may down-regulate FVIIa, potentially explaining gender differences in cardiovascular risk.

Area of Science:

  • Cardiovascular Science
  • Hematology
  • Endocrinology

Background:

  • Men possess a higher cardiovascular risk than women, often attributed to the cardioprotective influence of female sex hormones.
  • This gender disparity may be linked to differences in the activation status of the coagulation system.

Purpose of the Study:

  • To compare plasma levels of activated factor VII (FVIIa) between men and women.
  • To investigate the impact of the menstrual cycle on FVIIa levels in women.

Main Methods:

  • A prospective study involving 20 healthy men and 20 healthy young women.
  • Measurement of plasma FVIIa and prothrombin fragment (F1 + 2) levels across different menstrual cycle phases.

Main Results:

Related Experiment Videos

  • Men consistently showed significantly higher FVIIa levels (60 mU/ml) compared to women throughout all menstrual cycle phases.
  • In women, FVIIa levels were highest during the follicular phase (41 mU/ml) and decreased during midcycle (34 mU/ml) and the luteal phase (33 mU/ml).
  • Prothrombin fragment (F1 + 2) levels decreased significantly during the midcycle and luteal phases in women.

    • Conclusions:

    • Plasma FVIIa levels are higher in men than in women.
    • Endogenous female sex hormones appear to down-regulate FVIIa during the menstrual cycle.
    • These hormonal influences on FVIIa may contribute to the observed gender differences in cardiovascular risk.